Skip to main content

Advertisement

Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease

Fig. 6

2ccPA-ameliorated EAE pathological condition and immunopathology. Mice treated with EAE + saline and EAE + 2ccPA were immunized with the MOG35−55 peptide and clinical scores were assessed daily for 30 days (a). Treatment with 2ccPA after the peak of EAE symptoms had occurred (b). Data are mean ± SEM, n = 5 animals. Statistical analysis was performed using two-way ANOVA followed by post hoc Mann-Whitney U test regarding day 0–30 (a) or day 17–30 (b), respectively, (**p < 0.01; ***p < 0.001 vs. EAE + saline). H&E staining revealed histological features of MOG35−55-induced EAE. Control (c), EAE + saline (d), EAE + 2ccPA (e). The degrees of inflammation (f). Scale bar = 50 μm. Immunostaining with T cell and macrophage infiltration in the spinal cord. Fluorescence for CD4, DAPI, and marge images. Control (g), EAE + saline (h), EAE + 2ccPA (i). Number of infiltrating T cells in the spinal cord (m). Fluorescence for F4/80, DAPI, and marge images. Control (j), EAE + saline (k), EAE + 2ccPA (l). Number of infiltrating macrophages in the spinal cord (n). Data are mean ± SEM, n = 5 animals. Statistical analysis was performed using one-way ANOVA followed by post hoc Newman-Keuls test (**p < 0.01; ***p < 0.001 vs. control; # p < 0.05; ### p < 0.001 vs. EAE + saline). Scale bar = 100 μm

Back to article page